SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2552That's why I said to do it with an extra chunk, not one's core. Then gettom pope-10/25/2010
2551I'm talking about the opportunity loss if MNTA has a huge upward spike and yDewDiligence_on_SI-10/25/2010
2550Good point, if you expect MNTA to fall by more than the amount of the premium. Utom pope-10/25/2010
2549<i>>So far [selling covered calls] has worked well.<</i> Of cDewDiligence_on_SI-10/25/2010
2548>>Selling covered calls, which some posters have reported doing from time IRWIN JAMES FRANKEL-10/25/2010
2547>>CAMBRIDGE, Mass., Oct. 25, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceutictuck-10/25/2010
2546Given the IV's, a covered call on the NOV 15's would be attractive, but tom pope-10/25/2010
2545This is pretty normal for Momenta options. I see IVs double that near binary evtuck-10/25/2010
2544I hope to be nimble; because of the Teva shell game, I would expect a spike to btuck-10/25/2010
2543Very high volatility levels lead to high premia - around 70 in the case of the Ntom pope-10/25/2010
2542I don’t play with options at all. It’s hard to enough to figure out the directioDewDiligence_on_SI-10/25/2010
2541"Try not to miss the forest for the trees :-)" Are you saying that deJeffry K. Smith-10/25/2010
2540<i>Momenta <b>pooped</b> slightly on the news</i> I thiJeffry K. Smith-10/25/2010
2539Biogenerics article from The Economist. economist.com Pharmaceuticals Attack rkrw-10/25/2010
2538And if GM turns out to be lower for some reason,.....it seemed the marginal GM wRobohogs-10/25/2010
2537<i>>With that in mind, I am planning on cashing my trading shares for cDewDiligence_on_SI-10/25/2010
2536Since the fairly significant sales beat by m-enoxaparin last week I have seen notuck-10/25/2010
2535Thanks for sharing. hope all is well.mopgcw-10/22/2010
2534I actually bothered to listen to this morning's webcast. Don't think thtuck-10/22/2010
2533Ah, that was a higher inventory number than I was using. Forgive me for sleepintuck-10/21/2010
2532Based on the CC, I think NVS has a $1.1B inventory-adjusted run rate. The calculDewDiligence_on_SI-10/21/2010
2531m-enoxaparin sales of $292 million by Sandoz: novartis.com Hard to call the rutuck-10/21/2010
2530MNTA ‘ReadMeFirst’ updated: <i>generic Lovenox has 45% market share; CanaDewDiligence_on_SI-10/18/2010
2529My only comment is - I felt better when Hurvitz/Barrett/Suesskind were behind thidos-10/12/2010
2528Bought my second lot under $13.60...I can almost palpate the bearishness in the SeachRE-10/12/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News